 |
Trial Information
Summary: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast CancerStatus: No longer recruiting Protocol Number: BO16348 Sponsor: F Hoffman-La Roche Ltd Company Division: Pharmaceutical Official Scientific Title: A randomized, open-label study of the effect of Herceptin on disease-free and overall survival in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy Brief Summary: This study will compare the efficacy and safety of different treatment durations of intravenous Herceptin compared to observation (no treatment) in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy. The anticipated time on study treatment is 2+ years, and the target sample size is 500+ individuals. Target sample size is 4482. Study Phase: III Study Design / Study Details:
Study Type: Interventional
Condition: Breast Cancer Intervention Type: Drug Intervention Name: trastuzumab[Herceptin] Primary Outcome: 1. Disease-free survival Key Secondary Outcomes: 1. Efficacy: Overall survival, relapse-free survival, distant disease-free survival. Safety: Adverse events, with special emphasis on cardiac safety, laboratory parameters. Inclusion Criteria:
Exclusion Criteria:
Gender: Females Age Limits: Min: 18 Years Accepts Healthy Volunteers: No Anticipated Start Date: December, 2001 Trial Registration Date: 06/24/2005 Date Last Updated: 08/18/2008
This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Trial listings updated: September 2, 2008 at 1:46:27 PM |
|
|
Patient Resources: [ Trial Listing
] [ Notification Services ] [ Drug
Directories ]
Copyright © 1995 - 2008, CenterWatch |
